Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Thirty years of recombinant BCG: new trends for a centenary vaccine

Full text
Author(s):
Marques-Neto, Lazaro M. [1] ; Piwowarska, Zuzanna [1, 2] ; Kanno, I, Alex ; Moraes, Luana [3, 4] ; Trentini, Monalisa M. [3] ; Rodriguez, Dunia [3] ; Silva, Jose L. S. C. [3, 4] ; Leite, Luciana C. C. [3]
Total Authors: 8
Affiliation:
[1] Inst Butantan, Lab Desenvolvimento Vacinas, Sao Paulo - Brazil
[2] Univ Claude Bernard Lyon 1, UnivLyon, Villeurbanne - France
[3] Kanno, Alex, I, Inst Butantan, Lab Desenvolvimento Vacinas, Sao Paulo - Brazil
[4] USP Inst Butantan IPT, Programa Posgrad Interunidades Biotecnol, Sao Paulo - Brazil
Total Affiliations: 4
Document type: Review article
Source: EXPERT REVIEW OF VACCINES; v. 20, n. 8 JUL 2021.
Web of Science Citations: 0
Abstract

Introduction: Global perception of the potential for Bacille Calmette-Guerin (BCG), and consequently recombinant BCG (rBCG), in a variety of prophylactic and therapeutic applications has been increasing. A century of information on BCG, and three decades of experience with rBCG, has generated solid knowledge in this field. Area covered: Here, we review the current state of knowledge of BCG and rBCG development. Molecular tools have facilitated the expression of a variety of molecules in BCG, with the aim of improving its efficacy as a tuberculosis vaccine, generating polyvalent vaccines against other pathogens, including viruses, bacteria, and parasites, and developing immunotherapy approaches against noninvasive bladder cancer. BCG's recently appraised heterologous effects and prospects for expanding its application to other diseases are also addressed. Expert opinion: There are high expectations for new tuberculosis vaccines currently undergoing advanced clinical trials, which could change the prospects of the field. Systems biology could reveal effective biomarkers of protection, which would greatly support vaccine development. The development of appropriate large-scale production processes would further support implementation of new vaccines and rBCG products. The next few years should consolidate the broader applications of BCG and produce insights into improvements using the recombinant BCG technology. (AU)

FAPESP's process: 17/24832-6 - Development of vaccines based on recombinant BCG: Tuberculosis, Pertussis, Pneumococcus and Schistosoma
Grantee:Luciana Cezar de Cerqueira Leite
Support Opportunities: Research Projects - Thematic Grants